| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8008338 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9216167 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(a month from now) | |
| US8906950 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(a month from now) | |
| US9216127 | ABBVIE | Burial vault and method for customizing a burial vault |
May, 2024
(a month from now) | |
| US8541463 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(a month from now) | |
| US8648107 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(a month from now) | |
| US8946281 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(a month from now) | |
| US8377982 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(a month from now) | |
| US8207215 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(a month from now) | |
|
US8207215 (Pediatric) | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2024
(7 months from now) | |
|
US8377982 (Pediatric) | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2024
(7 months from now) | |
|
US8541463 (Pediatric) | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2024
(7 months from now) | |
|
US8008338 (Pediatric) | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2027
(3 years from now) | |
Acular Ls is owned by Abbvie.
Acular Ls contains Ketorolac Tromethamine.
Acular Ls has a total of 13 drug patents out of which 0 drug patents have expired.
Acular Ls was authorised for market use on 30 May, 2003.
Acular Ls is available in solution/drops;ophthalmic dosage forms.
Acular Ls can be used as a method of treating or reducing ocular pain and burning/stinging, a method of treating or preventing ocular pain in a patient, a method of treating ocular pain and/or enhancing ocular comfort, a method of treating or preventing ocular pain and burning, a method of treating ocular pain, a method of controlling postoperative ocular pain and burning/stinging in a patient, a method of treating or preventing ocular pain and burning/stinging following corneal surgery.
The generics of Acular Ls are possible to be released after 24 November, 2027.
Drugs and Companies using KETOROLAC TROMETHAMINE ingredient
Market Authorisation Date: 30 May, 2003
Treatment: A method of treating ocular pain and/or enhancing ocular comfort; A method of treating or preventing ocular pain and burning; A method of treating or reducing ocular pain and burning/stinging; A metho...
Dosage: SOLUTION/DROPS;OPHTHALMIC
ACULAR LS family patents
